Evidence map›Paper›PMID 29282600›Full record

ArticleAnnals of surgical oncology2018

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.

Tommaso Cornali, Paolo Sammartino, Nikolaos Kopanakis, Athina Christopoulou, Marialuisa Framarino Dei Malatesta, Elias Efstathiou, Alessandra Spagnoli, Antonio Ciardi, Daniele Biacchi, John Spiliotis

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Tommaso CornaliDepartment of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
Paolo SammartinoDepartment of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy. paolo.sammartino@uniroma1.it.
Nikolaos KopanakisFirst Department of Surgical Oncology, Metaxa Cancer Hospital, Pireaus, Greece.
Athina ChristopoulouMedical Oncology Unit, S. Andrew Hospital, Patras, Greece.
Marialuisa Framarino Dei MalatestaDepartment of Gynecology, Obstetric and Urological Science, Oncologic Day-Hospital, Sapienza University of Rome, Rome, Italy.
Elias EfstathiouFirst Department of Surgical Oncology, Metaxa Cancer Hospital, Pireaus, Greece.
Alessandra SpagnoliDepartment of Public Health and Infection Disease, Statistics Section, Sapienza University of Rome, Rome, Italy.
Antonio CiardiDepartment of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Daniele BiacchiDepartment of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.
John SpiliotisFirst Department of Surgical Oncology, Metaxa Cancer Hospital, Pireaus, Greece.
Sapienza University of Rome · ITMetaxa Hospital · GRGeneral University Hospital of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).

methodsThis study analyzed clinical, pathologic, and treatment data for patients with peritoneal metastases from EC who underwent CRS plus HIPEC at two tertiary centers. The outcome measures were morbidity, overall survival (OS), and progression-free survival (PFS) during a median 5 year follow-up period. Uni- and multivariate analyses were performed to identify significant factors related to outcome.

resultsA total of 33 patients met the inclusion criteria and completed the follow-up period. At laparotomy, the median peritoneal cancer index (PCI) was 15 (range 3-35). The CRS procedure required a mean 8.3 surgical procedures per patient, and for 22 patients (66.6%), a complete cytoreduction was achieved. The mean hospital stay was 18 days, and major morbidity developed in 21% of the patients. The operative mortality was 3%. When surgery ended, HIPEC was administered with cisplatin 75 mg/m

conclusionsFor selected patients with peritoneal metastases from EC, when CRS leaves no residual disease, CRS plus HIPEC achieves outcomes approaching those for other indications such as colon and ovarian carcinoma.

Indexed as

AdultAgedChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHyperthermia, InducedMiddle AgedPeritoneal NeoplasmsPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID29282600
PMCPMC5814516
OpenAlexW2776390301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.